Last reviewed · How we verify

NCT05717686

A Study Evaluating AHB-137 in Healthy Participants and Participants with Chronic Hepatitis B

Completed Phase 1 Last updated 14 February 2025
What this trial tests

Phase 1 trial testing AHB-137 injection in Chronic Hepatitis B in 64 participants. Completed in 7 January 2025.

Timeline
28 February 2023
Primary endpoint
7 January 2025
7 January 2025

Quick facts

Lead sponsorAusperBio Therapeutics Inc.
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingquadruple
Primary purposetreatment
Enrollment64
Start date28 February 2023
Primary completion7 January 2025
Estimated completion7 January 2025
Sites9 locations across Hong Kong, New Zealand, United States, Taiwan

Drugs / interventions tested

Conditions studied

Sponsor

AusperBio Therapeutics Inc. — full company profile →

Who can join

Adults 18 to 65, any sex, with Chronic Hepatitis B. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to evaluate the safety, tolerability, and pharmacokinetics of AHB-137 subcutaneous injection in healthy volunteers and in chronic hepatitis B (CHB) patients after single and multiple doses. In addition, the study will evaluate the initial antiviral efficacy of AHB-137 in CHB patients following a multiple dosing regimen.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

  1. Landscape of small nucleic acid therapeutics: moving from the bench to the clinic as next-generation medicines.
    Liu M, Wang Y, Zhang Y, Hu D, et al · · 2025 · cited 62× · PMID 40059188 · DOI 10.1038/s41392-024-02112-8
  2. Current trends and advances in antiviral therapy for chronic hepatitis B.
    Li J, Liu S, Zang Q, Yang R, et al · · 2024 · cited 7× · PMID 38945693 · DOI 10.1097/cm9.0000000000003178
  3. Small nucleic acid drugs-the dawn of functional cure of chronic hepatitis B.
    Zhang L, Cao Y, Zhuang S, Sun J, et al · · 2025 · cited 1× · PMID 41079747 · DOI 10.3389/fphar.2025.1633001
  4. [Clinical research advances for small-molecule nucleic acid drugs in the treatment of chronic hepatitis B].
    Wang WX, Guo YM, Fei ZX, Zhu SS, et al · · 2025 · PMID 41461559 · DOI 10.3760/cma.j.cn501113-20250114-00026

Verify or expand the search:

Other recruiting trials for Chronic Hepatitis B

Currently open trials in the same condition.

Other AusperBio Therapeutics Inc. trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05717686.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing